Dr. Cynthia Verst is president, Design and Delivery Innovation, Research & Development Solutions at IQVIA. In this role Dr. Verst is responsible for driving innovation and transformation throughout the trial lifecycle. Having previously served as president of both clinical operations and real world and late phase research for IQVIA, Dr. Verst brings a holistic and comprehensive view of clinical research, and champions the advanced use of real-world data, analytics and technology to advance therapies for patients. Recognized by FierceBiotech as a top woman in biotech, and as a PharmaVoice Top 100 leader, she currently sits on the Board of Directors for ACROand is president-elect of the DIA Board of Directors.

Prior to joining IQVIA (then Quintiles), she served as senior vice president, Global Late Phase Research for OptumInsight (a division of UnitedHealth Group), where she and her team successfully established and grew a new global Late Phase Research Business Unit. Dr. Verst began her career in biopharma at Procter & Gamble Pharmaceuticals as section head in its North American Medical and Technical Affairs group, successfully leading the Phase IIIB/IV research requirements of marketed products.

Dr. Verst holds a doctorate and bachelor’s degree in Pharmacy from the University of Cincinnati, a master’s degree in Structural and Cellular Biology from the University of Illinois, and bachelor’s degrees in Biology and Chemistry from Northern Kentucky University.